PRAX
Praxis Precision Medicines, Inc. Common Stock
stockNASDAQ
praxis precision medicines, inc., a clinical-stage biopharmaceutical company, develops therapies for central nervous system disorders characterized by neuronal imbalance. its lead product candidates include prax-114, an extrasynaptic-preferring gabaa receptor positive allosteric modulator that is in phase iia clinical trial for the treatment of major depressive disorder and perimenopausal depression; and prax-944, a selective small molecule inhibitor of t-type calcium channels, which is in phase iia clinical trial for the treatment of essential tremor. the company is also developing prax-562, a persistent sodium current blocker that is in phase i clinical trial to treat severe pediatric epilepsy and adult cephalgia; prax-222, an antisense oligonucleotide for patients with gain-of-function (gof) scn2a epilepsy; and kcnt1 program for the treatment of kcnt1 gof epilepsy. it has a cooperation and license agreement with rogcon inc.; a license agreement purdue neuroscience company; and a res
| Period | Price | Date | Change | Beta |
|---|---|---|---|---|
| 1W | 285.65 | 2026-09-28 | +3.46% | 1.775 |
| 1M | 351.81 | 2026-09-04 | -16.00% | 1.249 |
| 3M | 313.50 | 2026-07-06 | -5.74% | 0.701 |
| 6M | 310.11 | 2026-04-06 | -4.71% | 0.958 |
| 1Y | 54.38 | 2025-10-03 | +443.44% | 0.393 |
| 2Y | 64.94 | 2024-10-04 | +355.07% | — |
| 5Y | 283.95 | 2021-10-04 | +4.08% | 0.999 |
Praxis Precision Medicines, Inc. Common Stock (NASDAQ:PRAX) stock price today is $295.52, and today's volume is 456,099. PRAX is up 3.001% today. The 30 day average volume is 410,846. PRAX market cap is $8.25B with 27.92M shares outstanding.